Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

Real-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for patients with HCV infection and compensated cirrhosis is limited, especially for the 8-week regimen and in an Asian population. This retrospective study enrolled 159 consecutive patients with HCV and compensated cirrhosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yung-Hsin, Lu, Chung-Kuang, Chen, Chun-Hsien, Hsieh, Yung-Yu, Tung, Shui-Yi, Chen, Yi-Hsing, Yen, Chih-Wei, Tung, Wei-Lin, Chang, Kao-Chi, Chen, Wei-Ming, Lu, Sheng-Nan, Hung, Chao-Hung, Chang, Te-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387785/
https://www.ncbi.nlm.nih.gov/pubmed/35980912
http://dx.doi.org/10.1371/journal.pone.0272567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387785/
https://www.ncbi.nlm.nih.gov/pubmed/35980912
http://dx.doi.org/10.1371/journal.pone.0272567

Ejemplares similares